Aileron Therapeutics

85 articles with Aileron Therapeutics

• 

  Clinical Catch-Up: Amgen, AstraZeneca, Avillion Attack Asthma

  5/23/2022

  Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.

• Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

  5/19/2022

  Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer.

• Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  Aileron Therapeutics announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. ET in Miami, FL.

• Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

  5/13/2022

  Aileron Therapeutics today announced that it will host a virtual KOL investor event on Thursday, May 19, 2022, at 4:00 pm ET/ 1:00 pm PT.

• Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming SID 2022 Annual Meeting

  5/10/2022

  Aileron Therapeutics announced a late-breaking oral presentation at the upcoming Society for Investigative Dermatology Annual Meeting, which will be held May 18 – 21, 2022 in Portland, Oregon.

• Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

  5/5/2022

  Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the first quarter ended March 31, 2022.

• Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations

  4/21/2022

  Aileron Therapeutics announced it has expanded its management team with the appointment of Christopher Zergebel as Vice President of Program Management and Clinical Operations.

• Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

  3/28/2022

  Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2021.

• Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference

  3/22/2022

  Aileron Therapeutics announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will provide a company overview at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, which will take place March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

• Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones

  1/5/2022

  Aileron Therapeutics, a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective to save more patients’ lives, provided a business update and outlined the company’s strategic priorities for 2022.

• Aileron Therapeutics to Present at Upcoming Investor Conferences - Jan 04, 2022

  1/4/2022

  Aileron Therapeutics is pleased to announce that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will provide a company overview and business update at the H.C. Wainwright BIOCONNECT Conference, which will be held virtually January 10th – 12th and the Emerging Growth Conference, which will be held virtually on January 5th.

• Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs

  12/20/2021

  Aileron Therapeutics (NASDAQ:ALRN) today issued the following statement regarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who served as a member of the company's Scientific Advisory Board since 2011.

• Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

  11/12/2021

  Aileron Therapeutics today reported financial results and business highlights for the third quarter ended September 30, 2021.

• Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity

  10/7/2021

  Aileron Therapeutics (Nasdaq: ALRN), today presented new preclinical data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021 on ALRN-6924, currently in development as a novel, selective chemoprotective agent.

• Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021

  9/30/2021

  Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced it will present new preclinical data at the upcoming AACR-NCI-EORTC International Conference.

• 

  Clinical Catch-Up: September 13-17

  9/20/2021

  With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.

• Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent

  9/16/2021

  Aileron Therapeutics today presented new clinical data at the European Society of Medical Oncology (ESMO) Virtual Congress 2021 supporting ALRN-6924’s best-in-class potential as a chemoprotective agent.

• Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924

  9/10/2021

  Aileron Therapeutics today announced two upcoming poster presentations at the European Society of Medical Oncology (ESMO) Virtual Congress 2021, which is being held September 16-21, 2021.

• Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting

  8/27/2021

  Aileron Therapeutics today announced a poster presentation showcasing initial findings from its ongoing study of ALRN-6924 in healthy volunteers at the International Society for Experimental Hematology (ISEH) 50th Annual Scientific Meeting, which is currently underway.

• Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/11/2021

  Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today reported business highlights and financial results for the second quarter ended June 30, 2021.